Obtaining and Managing REMS Patents: What Patent Prosecutors Need to Know, USPTO and FDA Policies and Rules
March 21, 2023
Webinar
Strafford Publications
As part of the Strafford Publications’ webinar series, Finnegan partners Mark Feldstein and Thomas Irving will provide guidance on issues surrounding Risk Evaluation and Mitigation Strategy (REMS) patents and listing in the Orange Book. They will also discuss REMS patents and what patent prosecutors need to know avoid. For more information, or to register, please see Strafford’s website.
Tags
Orange Book, United States Patent and Trademark Office (USPTO), Food and Drug Administration (FDA)
